A61K 2239/51
Stomach
A61K2239/51 (Stomach) appears on 26 US grants and 67 published applications in this corpus.
Search patents in A61K- Granted patents
- 26
- Published applications
- 67
- Assignees
- 61
- Inventors
- 188
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 3 |
| 2017 | 0 | 3 |
| 2018 | 2 | 1 |
| 2019 | 1 | 6 |
| 2020 | 1 | 6 |
| 2021 | 2 | 3 |
| 2022 | 4 | 8 |
| 2023 | 3 | 10 |
| 2024 | 3 | 10 |
| 2025 | 4 | 6 |
| 2026 | 3 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Histone deacetylase inhibitors for use in immunotherapy22 Sep 2026US 12,740,986 B2Viracta Subsidiary, Inc.
- Modified K562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production16 Jun 2026US 12,655,391 B2Gene Solutions Joint Stock Company
- Prevention or mitigation of T-cell engaging agent-related adverse effects19 May 2026US 12,629,419 B2Hoffmann-La Roche Inc.
- HDAC inhibitors for use with NK cell based therapies30 Sep 2025US 12,427,152 B2NantKwest, Inc.
- Natural killer cells exhibiting increased anticancer activity and immunotherapeutic use thereof3 Jun 2025US 12,319,936 B2Cha Biolab Co., Ltd.
- Hdac inhibitors for use with nk cell based therapies24 Sep 2026US 2026/0284060 A9NantKwest, Inc.
- Histone deacetylase inhibitors for use in immunotherapy24 Sep 2026US 2026/0284061 A9Viracta Subsidiary, Inc.
- Anti-5t4 antibody-natural killer cell conjugate and use thereof23 Jul 2026US 2026/0207746 A1Imbioray (Hangzhou) Biomedicine Co., Ltd.
- Cd138/syndecan1 antibodies and methods of use thereof14 May 2026US 2026/0131036 A1
- Cancer immunotherapy16 Apr 2026US 2026/0102420 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation16US 6,544,787 B1Baxter International Inc. · 2003
- Process for induction culture of cytotoxic T lymphocytes having killing activity against tumor cells6US 5,874,307 AThe Institute of Physical and Chemical Research · 1999
- Method of treating malignancies5US 6,022,538 AThe Wistar Institute of Anatomy and Biology · 2000
- Cancer vaccines and vaccination methods4US 10,137,182 B2ImmunoCellular Therapeutics, Ltd. · 2018
- Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof4US 10,377,822 B2Carsgen Therapeutics Co., Ltd. · 2019